OR WAIT 15 SECS
Doctors Shepard, Kraus Augment Senior Level Experience in Key Therapeutic Areas
BASKING RIDGE, NJ, June7, 2005 -- i3 Research announced today the hiring of two senior level physicians: Robert C. Shepard, MD, FACP, as senior medical director of Oncology; and Carl N. Kraus, MD, as medical director of Respiratory and Infectious Disease (RID). The two illustrate the importance the CRO places on therapeutic specialization by augmenting at the highest levels two of i3's three areas of therapeutic focus. The CRO's third therapeutic focus is Central Nervous System.
Dr. Shepard will support i3 Research in protocol design, training and consulting in North America and abroad. He comes to the i3 Oncology team from AstraZeneca Pharmaceuticals, where he was medical director of oncology clinical research and development; prior to that he was a medical officer in the oncology branch of the Food and Drug Administration. Dr. Shepard's extensive experience in clinical research in hematology/oncology includes full-time academic appointments at both Tufts University and the University of Virginia, where he served as associate professor and primary investigator for the Eastern Cooperative Oncology Group, a leading National Cancer Institute cancer clinical trial group, and director of gastrointestinal and genitourinary oncology.
After earning his A.B. degree in biochemistry and molecular biophysics, magna cum laude, from Harvard College, he received his M.D. degree from Duke University, and did house officer training at Cornell and at the Boston VA Medical Center. He served his fellowship in hematology and oncology at Tufts-New England Medical Center and at the Dana-Farber Cancer Center at Harvard. He has published extensively in the peer-reviewed literature, and is certified by the American Boards of Internal Medicine, Hematology, and Medical Oncology. He has numerous memberships in the learned professional societies including ASCO, AACR, ASH, and ESMO.
Dr. Kraus is board certified in Internal Medicine and Infectious Diseases, and will help manage the i3 Respiratory and Infectious Disease practice, also assisting with training, protocol design and consulting. He joins i3 from the Food and Drug Administration, where he has served since 2002 as medical officer, Infectious Diseases, in the division of special pathogen and immunologic drug products. He earned his B.A. from Washington University in St. Louis and his M.D. from the School of Medicine of Washington University. He served both his internship and residency in Internal Medicine at the University of Chicago Hospitals, and his fellowship at the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He then held a two-year appointment as Clinical Associate in the Tuberculosis Research Section of the NIAID, NIH.
i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It comprises: i3 Research, a therapeutically specialized contract research organization; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; i3 Magnifi, delivering the science and solutions to achieve marketplace success, and; i3 DLN, providing continuing medical education. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit www.i3global.com.